Dr Mike Jones – Managing Director – Impact Minerals (ASX:IPT) is an exploration company listed on the ASX in November 2006. The Company manages extensive tenement holdings (>4,000 km2) within Australia featuring significant potential for high-grade mineral deposits of gold, silver, lead, zinc, copper, nickel and PGM’s.
Copyright 2023 – Finance News Network
23 Feb 2024 - Discover Sunshine Metals' strategic focus on Queensland's prolific gold and base metal districts, unveiling promising exploration ventures and recent resource upgrades.
17 Dec 2019 - Wisr Limited (ASX:WZR) CEO, Anthony Nantes talks about the company's partnership with NAB to provide an initial $50m in funding to support its personal loan book and diversify its funding partners.
15 Jul 2024 - Allan Mason, the former accountant to Kerry Packer during the height of his notoriety, speaks about his best-selling book and tips for cutting back tax costs.
23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
07 Sep 2023 - Empire Energy Group (ASX:EEG) CEO Alex Underwood discusses large scale future well drilling projects, and anticipates commercial production by 2025.
27 Sep 2021 - PropTech Group Limited (ASX:PTG) CEO and Managing Director Joe Hanna introduces the company's suite of market-leading real estate software solutions, discussing FY21 results and outlook.
24 Nov 2020 - Mitchell Services Limited (ASX:MSV) CEO Andrew Elf provides an update on the company's FY20 results, its strategy of becoming Australia’s leading drilling services provider and the robust state of the mining sector.
01 Aug 2023 - QX Resources Limited (ASX:QXR) Managing Director Steve Promnitz discusses progress with the company's lithium project in California, including permitting, access to water and timeline ahead.
09 Dec 2020 - Alterity Therapeutics Limited (ASX:ATH) Chairman and CEO Geoffrey Kempler provides an update on the company's lead compound ATH434 for Multiple System Atrophy, its dual strategy in Europe and the US and its Phase 2 plans.
